Found: 13
Select item for more details and to access through your institution.
Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2018, v. 144, n. 3, p. 601, doi. 10.1007/s00432-017-2574-4
- By:
- Publication type:
- Article
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 2, p. 159, doi. 10.3390/ph14020159
- By:
- Publication type:
- Article
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 184, n. 2, p. 421, doi. 10.1007/s10549-020-05856-3
- By:
- Publication type:
- Article
Early Changes of the Standardized Uptake Values (SUV max) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
- Published in:
- Cancers, 2020, v. 12, n. 11, p. 3314, doi. 10.3390/cancers12113314
- By:
- Publication type:
- Article
Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the 'biological window therapy'.
- Published in:
- Breast Cancer Research & Treatment, 2014, v. 144, n. 1, p. 113, doi. 10.1007/s10549-014-2840-y
- By:
- Publication type:
- Article
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.686776
- By:
- Publication type:
- Article
Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2006, v. 57, n. 2, p. 185, doi. 10.1007/s00280-005-0028-1
- By:
- Publication type:
- Article
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00579-2
- By:
- Publication type:
- Article
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00579-2
- By:
- Publication type:
- Article
Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-38760-z
- By:
- Publication type:
- Article